Meeting of the Parliament 24 October 2023
I welcome the opportunity to speak in this important debate. As always, I extend my gratitude to the campaigners, medical professionals, researchers and constituents whose invaluable efforts continue to put the important issue of transvaginal mesh implants on the agenda.
Once deemed a medical solution, transvaginal mesh implants have now become a source of debilitating complications for many people across Scotland. As we are aware from the numerous occasions on which the issue has been debated in the chamber, the complications arising from implants are not merely physical but extend to psychological distress, too.
We have made significant progress in recent years, which we can confidently attribute to the joint efforts of campaigners and individuals who have been massively affected by the issue. I am absolutely certain that future generations will benefit from better healthcare thanks to their incredible work.
I acknowledge the work that the Scottish Government has undertaken to mitigate the suffering of the affected patients. Many of our constituents have suffered life-changing complications related to mesh implants, so I support the Scottish Government’s decision to establish a fund that will support those with mesh complications, providing a semblance of relief to patients and their families. I am proud that Scotland is the first UK country to reimburse people for private treatment that was previously sought. That is a reflection of our commitment to providing holistic care and financial support to those who are in need.
Despite those significant achievements, there is more to be done, which brings me to the main focus of the motion: the transvaginal mesh case record review. The review has been a massive and impressive undertaking by Professor Alison Britton of Glasgow Caledonian University, and I commend the 18 women who came forward to have their case records reviewed as part of it. The review is a significant initiative commissioned by the Scottish Government to address the profound concerns that women have raised. Their experiences will be integral in informing the future of mesh procedures. We must take this important opportunity to learn from their experiences.
As a member of the Health, Social Care and Sport Committee and the Citizen Participation and Public Petitions Committee, I have had the privilege of hearing invaluable evidence from medical advisers, NHS experts, campaign groups and, most importantly, patients. The recommendations in Professor Britton’s review are very much consistent with the evidence that the health committee has taken over the years. The committee evidence sessions have helped us to ensure that patients’ voices are heard, amplified and carefully considered. I thank each and every one of our witnesses for their influential contributions.
The discourse surrounding transvaginal mesh has brought to the fore the importance of ensuring that medical interventions are not only safe and effective but transparently documented and communicated to patients. The unanimous backing of the Patient Safety Commissioner for Scotland Bill earlier this year exemplifies Scotland’s commitment to amplifying the voice of patients, including those who are impacted by mesh implant complications, and will drive safety improvements across our health service. Insights from the review are a testament to the collective endeavour of addressing the concerns of affected individuals and improving the standards of patient care.